{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:58:15Z","timestamp":1793059095142,"version":"4.5.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title\/>\n                  <jats:p>Thymomas comprise a group of rare epithelial neoplasms of the anterior mediastinum. Whereas localized disease carries a favorable prognosis, the majority of patients with metastatic thymomas experience progression or recurrence over a 10-year period. Although targeted therapies have become standard of care in many malignancies, no clinically actionable mutations have consistently been identified in metastatic thymomas. Here, we describe a patient with an aggressive thymoma complicated by extensive pleural metastases. Over a 16-year period, she progressed on multiple treatment regimens. To identify additional treatment options, tissue from a pleural metastasis was sent for next-generation sequencing, revealing mutations in BRCA2, tyrosine kinase 2, and SET domain containing 2. Based on supporting evidence for poly (ADP-ribose) polymerase (PARP) inhibition in other BRCA-mutated tumors, the patient was started on the PARP inhibitor olaparib. She derived significant clinical benefit from treatment, with imaging showing overall stabilization of her disease. Here, we review the genotyping results of her tumor and discuss the functional and clinical significance of the mutations in her cancer as well as implications for managing patients with advanced BRCA-mutant thymomas.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key Points<\/jats:title>\n                  <jats:p>Targeted therapy has yet to enter the standard clinical management of metastatic thymomas. Patients with BRCA2-mutant thymomas may benefit from poly (ADP-ribose) polymerase inhibition.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2019-0393","type":"journal-article","created":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T19:05:39Z","timestamp":1572635139000},"page":"301-305","source":"Crossref","is-referenced-by-count":13,"title":["Metastatic Thymoma Harboring a Deleterious <i>BRCA2<\/i> Mutation Derives Durable Clinical Benefit from Olaparib"],"prefix":"10.1093","volume":"25","author":[{"given":"Daniel R.","family":"Principe","sequence":"first","affiliation":[{"name":"Medical Scientist Training Program, University of Illinois College of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suneel D.","family":"Kamath","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidayatullah G.","family":"Munshi","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisha A.","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,1]]},"reference":[{"key":"2021122510224859600_R1","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/bjc.2016.311","article-title":"PARP inhibitors for BRCA1\/2-mutated and sporadic ovarian cancer: Current practice and future directions","volume":"115","author":"Konecny","year":"2016","journal-title":"Br J Cancer"},{"key":"2021122510224859600_R2","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.leukres.2010.04.016","article-title":"BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: A review","volume":"34","author":"An","year":"2010","journal-title":"Leuk Res"},{"key":"2021122510224859600_R3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the treatment of breast cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"2021122510224859600_R4","doi-asserted-by":"crossref","first-page":"6373","DOI":"10.1158\/1078-0432.CCR-12-1627","article-title":"Personalized medicine in a phase I clinical trials program: The MD Anderson Cancer Center initiative","volume":"18","author":"Tsimberidou","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021122510224859600_R5","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1056\/NEJM200406173502523","article-title":"Thymic carcinoma with overexpression of mutated KIT and the response to imatinib","volume":"350","author":"Strobel","year":"2004","journal-title":"N Engl J Med"},{"key":"2021122510224859600_R6","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"2021122510224859600_R7","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1158\/1078-0432.CCR-17-0066","article-title":"Genomic analysis of thymic epithelial tumors identifies novel subtypes associated with distinct clinical features","volume":"23","author":"Lee","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2021122510224859600_R8","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1182\/blood-2015-08-664649","article-title":"Integrated genomic DNA\/RNA profiling of hematologic malignancies in the clinical setting","volume":"127","author":"He","year":"2016","journal-title":"Blood"},{"key":"2021122510224859600_R9","doi-asserted-by":"crossref","first-page":"7263","DOI":"10.4049\/jimmunol.176.12.7263","article-title":"Tyk2 negatively regulates adaptive Th1 immunity by mediating IL-10 signaling and promoting IFN-gamma-dependent IL-10 reactivation","volume":"176","author":"Shaw","year":"2006","journal-title":"J Immunol"},{"key":"2021122510224859600_R10","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.4049\/jimmunol.1303067","article-title":"Tyk2-dependent bystander activation of conventional and nonconventional Th1 cell subsets contributes to innate host defense against Listeria monocytogenes infection","volume":"192","author":"Hashiguchi","year":"2014","journal-title":"J Immunol"},{"key":"2021122510224859600_R11","doi-asserted-by":"crossref","first-page":"22840","DOI":"10.4161\/onci.22840","article-title":"Establishing the role of tyrosine kinase 2 in cancer","volume":"2","author":"Ubel","year":"2013","journal-title":"Oncoimmunology"},{"key":"2021122510224859600_R12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/0008-5472.CAN-08-1705","article-title":"Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance","volume":"69","author":"Simma","year":"2009","journal-title":"Cancer Res"},{"key":"2021122510224859600_R13","doi-asserted-by":"crossref","first-page":"50719","DOI":"10.18632\/oncotarget.9368","article-title":"SETD2: An epigenetic modifier with tumor suppressor functionality","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"2021122510224859600_R14","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"2021122510224859600_R15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bpa.12023","article-title":"Chromatin remodeling defects in pediatric and young adult glioblastoma: A tale of a variant histone 3 tail","volume":"23","author":"Fontebasso","year":"2013","journal-title":"Brain Pathol"},{"key":"2021122510224859600_R16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1186\/1471-2407-9-290","article-title":"The mRNA expression of SETD2 in human breast cancer: Correlation with clinico-pathological parameters","volume":"9","author":"Al Sarakbi","year":"2009","journal-title":"BMC Cancer"},{"key":"2021122510224859600_R17","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1182\/blood-2017-03-775569","article-title":"SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia","volume":"130","author":"Mar","year":"2017","journal-title":"Blood"},{"key":"2021122510224859600_R18","doi-asserted-by":"crossref","first-page":"21283","DOI":"10.1074\/jbc.M116.739375","article-title":"Structure\/function analysis of recurrent mutations in SETD2 protein reveals a critical and conserved role for a SET domain residue in maintaining protein stability and histone H3 Lys-36 trimethylation","volume":"291","author":"Hacker","year":"2016","journal-title":"J Biol Chem"},{"issue":"suppl 6","key":"2021122510224859600_R19","doi-asserted-by":"crossref","first-page":"vi31","DOI":"10.1093\/annonc\/mdr373","article-title":"BRCA in breast cancer: ESMO clinical practice guidelines","volume":"22","author":"Balmana","year":"2011","journal-title":"Ann Oncol"},{"key":"2021122510224859600_R20","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrc3181","article-title":"BRCA1 and BRCA2: Different roles in a common pathway of genome protection","volume":"12","author":"Roy","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"2021122510224859600_R21","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.athoracsur.2012.12.017","article-title":"BRCA1 gene mutation in thymic malignant melanoma","volume":"96","author":"Yi","year":"2013","journal-title":"Ann Thorac Surg"},{"key":"2021122510224859600_R22","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/gcc.20225","article-title":"Familial occurrence of thymoma and autoimmune diseases with the constitutional translocation t(14;20)(q24.1;p12.3)","volume":"44","author":"Nicodeme","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"2021122510224859600_R23","first-page":"333","article-title":"Does familial breast cancer and thymoma suggest a cancer syndrome?","volume":"573","author":"Zhang","year":"2015","journal-title":"A family perspective. Gene"},{"key":"2021122510224859600_R24","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: Genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol Oncol Res"},{"key":"2021122510224859600_R25","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41419-018-0357-8","article-title":"Atm reactivation reverses ataxia telangiectasia phenotypes in vivo","volume":"9","author":"Di Siena","year":"2018","journal-title":"Cell Death Dis"},{"key":"2021122510224859600_R26","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"2021122510224859600_R27","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci Signal"},{"key":"2021122510224859600_R28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/sj.bjc.6601656","article-title":"BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast\/ovarian cancer families","volume":"90","author":"Claes","year":"2004","journal-title":"Br J Cancer"},{"key":"2021122510224859600_R29","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1007\/s10549-012-2006-8","article-title":"Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel","volume":"133","author":"Laitman","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2021122510224859600_R30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/GIM.0b013e3181d38f2f","article-title":"Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2","volume":"12","author":"Petrucelli","year":"2010","journal-title":"Genet Med"},{"key":"2021122510224859600_R31","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.1128\/MCB.02248-06","article-title":"Poly(adp-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(adp-ribose) glycohydrolase","volume":"27","author":"Fisher","year":"2007","journal-title":"Mol Cell Biol"},{"key":"2021122510224859600_R32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/bcr417","article-title":"Distinct functions of BRCA1 and BRCA2 in double-strand break repair","volume":"4","author":"Liu","year":"2002","journal-title":"Breast Cancer Res"},{"key":"2021122510224859600_R33","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa1105535","article-title":"Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer","volume":"366","author":"Ledermann","year":"2012","journal-title":"N Engl J Med"},{"key":"2021122510224859600_R34","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N Engl J Med"},{"key":"2021122510224859600_R35","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"2021122510224859600_R36","first-page":"2154","article-title":"Niraparib maintenance therapy in platinum-sensitive","volume":"375","author":"Mirza","year":"2016","journal-title":"recurrent ovarian cancer. N Engl J Med"},{"key":"2021122510224859600_R37","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"2021122510224859600_R38","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/djy085","article-title":"Biomarkers for homologous recombination deficiency in cancer","volume":"110","author":"Hoppe","year":"2018","journal-title":"J Natl Cancer Inst"},{"key":"2021122510224859600_R39","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/s41467-017-00921-w","article-title":"Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes","volume":"8","author":"Riaz","year":"2017","journal-title":"Nat Commun"},{"key":"2021122510224859600_R40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","journal-title":"Nature"},{"key":"2021122510224859600_R41","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-repair defects and olaparib in metastatic prostate cancer","volume":"373","author":"Mateo","year":"2015","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2019-0393","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2019-0393","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/301\/41919909\/oncolo_25_4_301.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/25\/4\/301\/41919909\/oncolo_25_4_301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T10:23:32Z","timestamp":1640427812000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/25\/4\/301\/6443397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":41,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,11,1]]},"published-print":{"date-parts":[[2020,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2019-0393","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,4,1]]},"published":{"date-parts":[[2019,11,1]]}}}